Inactive Instrument

Vivione Biosciences Inc Stock

Equities

Investment Management & Fund Operators

Dynamic Chart
Vivione Biosciences Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018 CI
Vivione Biosciences Inc. Auditor Raises 'Going Concern' Doubt CI
Vivione Biosciences Inc. Auditor Raises 'Going Concern' Doubt CI
Vivione Biosciences Inc. Auditor Raises 'Going Concern' Doubt CI
Vivione Biosciences Inc. Announces Resignation of Lal Narang from the Board of Directors CI
Vivione Biosciences Inc. Announces Management Changes CI
Vivione Biosciences Inc. Primary Exchange Listing will Change to TSX Venture Exchange - Nex from TSX Venture Exchange CI
Vivione Biosciences Inc. announced that it has received $1 million in funding from Montalcino Holdings I, LLC CI
Vivione Biosciences Inc. announced that it expects to receive $2.5 million in funding from Montalcino Holdings I, LLC. CI
Vivione Biosciences Seeks Acquisitions CI
Vivione Biosciences Enters into Loan Agreement with Mr. Glenn Smith, Director CI
Vivione Biosciences Inc. Announces Resignation of Justin Springfield as Senior Vice President of Sales and Marketing CI
Vivione Biosciences Finalizes Agreement with University of Rochester for Exclusive Worldwide Rights to Novel Infectious Disease-Related Biomarker CI
Vivione Biosciences Inc. Announces A Research Collaboration with Northwestern University, Feinberg School of Medicine CI
Vivione Biosciences Inc. Auditor Raises 'Going Concern' Doubt CI
More news
Managers TitleAgeSince
Chief Executive Officer - -
Corporate Secretary - 14-01-28
Members of the board TitleAgeSince
Chief Executive Officer - -
Director/Board Member - -
More insiders
Vivione Biosciences Inc. is a technology and life sciences company. The Company is focused on rapid bacterial detection. The Company has developed a diagnostic system called RAPID-B, which tests bacteria in critical environments and provides quantitative results in approximately seven hours or less. Its RAPID-B is an integrated microbiology/infectious disease diagnostic system. Its primary targeting is accomplished with custom, optimized immuno-based reagents that are designed to target the cell surface of target bacteria without cross-reactivity to similar non-target bacteria. Its RAPID-B system has applications in various markets, including Hospitals, Universities and Clinics; testing system for bacterial detection and antimicrobial susceptibility profiles for bacterial infection in normally sterile body fluids, such as blood and urine, and detecting the presence of bacteria in blood and urine samples within minute's and days.
More about the company